SCHEMBL4785470

SCHEMBL4785470

O=[N+]([O-])c1ccc(-c2cccc(F)c2)c2nonc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 7/20 0.53
▸ TDO2 P48775 3/20 0.53
▸ MYC P01106 3/20 0.49
▸ MEN1 O00255 5/20 0.45
▸ KMT2A Q03164 5/20 0.45
▸ GSTP1 P09211 4/20 0.45
▸ GSTM2 P28161 4/20 0.45
▸ USP2 O75604 1/20 0.45
▸ POLB P06746 1/20 0.45
▸ TNNI3 P19429 1/20 0.45
▸ TNNT2 P45379 1/20 0.45
▸ TNNC1 P63316 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.44
▸ CYP2D6 P10635 1/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ HPGD P15428 1/20 0.44
▸ ALOX15 P16050 1/20 0.44
▸ ALOX12 P18054 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ HIF1A Q16665 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4787516 0.87 IDO1 (0.52) IDO1TDO2MYCMEN1KMT2A
SCHEMBL5281251 0.85 MEN1 (0.51) IDO1MYCMEN1KMT2AGSTP1
SCHEMBL4787872 0.84 IDO1 (0.53) IDO1MYCMEN1KMT2AGSTP1
SCHEMBL4787990 0.83 ARNT (0.47) IDO1TDO2MYCMEN1KMT2A
SCHEMBL5244876 0.83 IDO1 (0.60) IDO1TDO2MYCMEN1KMT2A
SCHEMBL5243642 0.83 MYC (0.67) IDO1MYCMEN1KMT2AGSTP1
SCHEMBL4787667 0.81 MEN1 (0.63) IDO1MYCMEN1KMT2AGSTP1
SCHEMBL5244760 0.80 MEN1 (0.53) IDO1TDO2MYCMEN1KMT2A
SCHEMBL5243120 0.77 KMT2A (0.52) IDO1MYCMEN1KMT2AGSTP1
SCHEMBL4784084 0.76 IDO1 (0.52) IDO1MYCMEN1KMT2AGSTP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1758873-A1 UBIQUITIN LIGASE INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2007-03-07 — — EP claimed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 — — WO claimed
US-20050282818-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-12-22 — — US claimed
WO-2008115259-A2 DERIVATIVES OF BENZOXADIAZOLE SUITABLE FOR THE TREATMENT OF CELL PROLIFERATIVE DISEASES RIGEL PHARMACEUTICALS, INC. (US) 2008-09-25 — — WO disclosed
WO-2008115259-A2 DERIVATIVES OF BENZOXADIAZOLE SUITABLE FOR THE TREATMENT OF CELL PROLIFERATIVE DISEASES RIGEL PHARMACEUTICALS, INC. (US) 2008-09-25 — — WO disclosed
EP-1758873-A1 UBIQUITIN LIGASE INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2007-03-07 — — EP disclosed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 — — WO disclosed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 — — WO disclosed
US-20050282818-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-12-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282818-A1 Ubiquitin ligase inhibitors NEDD4, TRAF6, XIAP IDO1 805/4885TDO2 2909/4885MYC 622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback